Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genekey Biotech
Chengdu, Sichuan, China
- Ownership
- Private
- Employees
- ~156
- Development stage
- Other
01
Overview
Genekey Biotech, a subsidiary of Salubris Pharmaceuticals, is currently in Phase 3 trials for its lead candidate SAL003 (an anti-PCSK9 monoclonal antibody) for hypercholesterolemia and SAL094 (an FSH fusion protein) for infertility. It is also advancing a bispecific antibody (JK07) for heart failure in Phase 1/2.
- Therapeutic areas
- Women's HealthEndocrinologyCardiovascularDermatologyOncology
- Modalities
- Monoclonal antibodyFusion proteinBispecific monoclonal antibodyRecombinant proteinGLP-1 receptor agonistBiosimilarGene therapy
- Industry
- Biotech
02
Partnerships
Salubris BiotherapeuticsLigand PharmaceuticalsSerum Institute of India
Beyond the preview
Go deeper on Genekey Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genekey Biotech.